Literature DB >> 2509555

Temporal development of protective cell-mediated and humoral immunity in BALB/c mice infected with Brucella abortus.

L N Araya1, P H Elzer, G E Rowe, F M Enright, A J Winter.   

Abstract

In BALB/c mice infected i.v. with attenuated strain 19 of Brucella abortus, the organism replicates to high numbers in the spleen and reaches peak concentrations at 2 wk postinfection (p.i.). The infection is then progressively cleared so that by 8 wk p.i. numbers of bacteria have decreased 10,000 fold or more. Passive transfer assays were performed with T cell-enriched spleen cells and serum of donor mice infected 2, 3, 4, 5, 6, or 8 wk previously. Antibodies conferred significant protection to recipients at and after 3 wk p.i., whereas protection by T cells was not evident until 4 wk p.i. The combined transfer of serum and cells enhanced protection over that provided by serum or cells alone when transfers were made before, but not after, challenge infection. Protection conferred by T cell-enriched spleen cells of 6-wk donors was unaffected by the presence of equal quantities of cells from 3-wk donors, but was abrogated by the removal of both CD4 and CD8 T cell subsets. Experiments with purified CD4 and CD8 subsets revealed that cell-mediated protection resided at equivalent levels in both subsets. Daily treatment of mice with Cyclosporin A for 4 wk after infection caused some increase in numbers of brucellae in spleens and livers. Although immune responses of treated animals were markedly suppressed, there was little effect of treatment on numbers of macrophages in the spleen, on enhanced killing of Listeria monocytogenes in the spleen, or on the nature and intensity of splenic and hepatic inflammatory responses. These data indicate that acquired resistance to infection with B. abortus in mice is the result of independent, and probably also interactive, effects of antibodies and T effector cells of both CD4 and CD8 phenotypes. The initial decline in bacterial numbers in the spleen, which occurred in the absence of detectable cell-mediated immunity in that organ, could probably be ascribed principally to effects of antibodies and to nonimmune stimuli responsible for increased formation, attraction, and activation of macrophages.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2509555

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  80 in total

1.  Cloning of a Brucella melitensis group 3 antigen gene encoding Omp28, a protein recognized by the humoral immune response during human brucellosis.

Authors:  L E Lindler; T L Hadfield; B D Tall; N J Snellings; F A Rubin; L L Van De Verg; D Hoover; R L Warren
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  Bacterial persistence and immunity in goats vaccinated with a purE deletion mutant or the parental 16M strain of Brucella melitensis.

Authors:  N F Cheville; S C Olsen; A E Jensen; M G Stevens; A M Florance; H S Houng; E S Drazek; R L Warren; T L Hadfield; D L Hoover
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

3.  Recombinant L7/L12 ribosomal protein and gamma-irradiated Brucella abortus induce a T-helper 1 subset response from murine CD4+ T cells.

Authors:  S C Oliveira; Y Zhu; G A Splitter
Journal:  Immunology       Date:  1994-12       Impact factor: 7.397

4.  Alteration of protective and serologic responses in BALB/c mice vaccinated with chemically modified versus nonmodified proteins of Brucella abortus 19.

Authors:  G W Pugh; L B Tabatabai
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

5.  Immune and pathologic responses in mice infected with Brucella abortus 19, RB51, or 2308.

Authors:  M G Stevens; S C Olsen; G W Pugh; M V Palmer
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

6.  Carboxyl-terminal protease regulates Brucella suis morphology in culture and persistence in macrophages and mice.

Authors:  Aloka B Bandara; Nammalwar Sriranganathan; Gerhardt G Schurig; Stephen M Boyle
Journal:  J Bacteriol       Date:  2005-08       Impact factor: 3.490

7.  Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant.

Authors:  A Al-Mariri; A Tibor; P Mertens; X De Bolle; P Michel; J Godefroid; K Walravens; J J Letesson
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

8.  Comparison of immune responses and resistance to brucellosis in mice vaccinated with Brucella abortus 19 or RB51.

Authors:  M G Stevens; S C Olsen; G W Pugh; D Brees
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

9.  Cloning and sequencing of yajC and secD homologs of Brucella abortus and demonstration of immune responses to YajC in mice vaccinated with B. abortus RB51.

Authors:  R Vemulapalli; A J Duncan; S M Boyle; N Sriranganathan; T E Toth; G G Schurig
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

10.  Effect of recombinant human macrophage colony-stimulating factor 1 on immunopathology of experimental brucellosis in mice.

Authors:  A G Doyle; W J Halliday; C J Barnett; T L Dunn; D A Hume
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.